NMRA
Neumora Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$1.31
−2.96%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
Market Cap
$246.14M
MomentumView details →
1D Return
−2.96%
YTD Return
−27.09%
RSI (14)
36.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
Market Cap
$246.14M
RSI (14)
36.2
MomentumView details →
1D Return
−2.96%
YTD Return
−27.09%
SummaryUpdated Jun 1, 2026
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Watertown, Massachusetts. The company went public in September 2023 and focuses on developing novel therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. Originally incorporated as RBNC Therapeutics, Inc., the company changed its name to Neumora Therapeutics in October 2021. Neumora is currently advancing multiple clinical-stage programs targeting conditions that affect approximately 1.5 billion people worldwide, with its lead program being navacaprant for major depressive disorder.
Similar companies
Latest newsMore news →
Paul L. Berns stepped down as Executive Chairperson of the Board of Directors of Neumora Therapeutics, Inc., effective August 14, 2026.22d agoDoron Sagman, M.D., FRCPC was appointed Chief Medical Officer of Neumora Therapeutics, Inc., effective August 14, 2026.22d agoJoshua Pinto, Ph.D. was promoted to Chief Executive Officer and President, and Class III director of the Board of Directors of Neumora Therapeutics, Inc., effective August 14, 2026.22d ago